CD274 and non-small cell lung carcinoma: The RATIONALE-303 study compared tislelizumab to docetaxel as second/third-line therapies in patients with advanced NSCLC achieved and found that tislelizumab prolonged the PFS (4.1 vs. 2.6 months, HR = 0.64, P < 0.0001) and OS (17.2 vs. 11.9 months, HR = 0.64, P < 0.0001), regardless of histology or PD-L1 expression.108